Drugs / Anagliptin
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01131091 | May → Nov 2010 | type 2 diabetes mellitus | Kowa Research Institute, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01169090 | Jul 2010 → Jul 2011 | type 2 diabetes mellitus | Kowa Research Institute, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00532506 | — | type 2 diabetes mellitus | Sanwa Kagaku Kenkyusho Co., Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01529528 | May 2011 → Sep 2012 | type 2 diabetes mellitus | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 3 | NCT01529541 | May 2011 → May 2013 | type 2 diabetes mellitus | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT07442006 | Oct 2025 → Mar 2027 expected | type 2 diabetes mellitus | JW Pharmaceutical | Recruiting | No outcome recorded |
| Phase 4 | NCT04810507 | Nov 2018 → Sep 2020 | type 2 diabetes mellitus | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 4 | NCT02312427 | Jan 2015 → Mar 2016 | congestive heart failure, diabetes mellitus | Mitsui Memorial Hospital | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 4 | NCT03014479 Comparator | Feb → Oct 2017 | type 2 diabetes mellitus | Takeda | Completed | Missed primary |
| Phase 4 | NCT02528019 Comparator | Aug 2015 → Aug 2017 | — | Kurume University | Unknown | No outcome recorded |
| Phase 4 | NCT02330406 Comparator | Apr 2015 → Jan 2018 | coronary artery disorder, hyperglycemia, low density lipoprotein cholesterol, mild elevation of, type 2 diabetes mellitus | Institute for Clinical Effectiveness, Japan | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anagliptin | “DPP-4 inhibitor (sitagliptin, vildagliptin, alogliptin, linagliptin, teneligliptin, anagliptin or saxagliptin) will be suspended for one month and serum BNP will be measured.” NCT02312427 ↗7“Alogliptin, anagliptin, linagliptin, saxagliptin, sitagliptin, teneligliptin or vildagliptin” NCT03014479 ↗ “anagliptin (100-200mg daily)” NCT02528019 ↗ |
| Known as | ANAGLIPTIN HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1929396 ↗ |
| Known as | Anagliptina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1929396 ↗ |
| Known as | Anagliptine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1929396 ↗ |
| Known as | CWP-403 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1929396 ↗ |
| Known as | SK-0403 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01169090 ↗ |
| Known as | Suiny | ChEMBL registry synonym — accepted as the source's own label CHEMBL1929396 ↗ |
| Action | Inhibit | “Anagliptin, one of the dipeptidyl peptidase-4 (DPP4) inhibiors” NCT02330406 ↗ |
| Modality | Small molecule | — CHEMBL1929396 ↗ |
| Route | Oral | “those in the anagliptin group receiving anagliptin 100 mg orally twice per day” PMID 29435776 ↗ Feb 2018 |
| Target | DPP4 | “Anagliptin, one of the dipeptidyl peptidase-4 (DPP4) inhibiors, was reported to reduce LDLC” NCT02330406 ↗ |